Continuous glucose monitoring (CGM) is being used with increasing frequency as an adjunct to self-monitoring of blood glucose in pregnancy, and novel targets based on CGM data are becoming standardized. This adoption of CGM is the result of its improving accuracy, patient preference, and evolving data demonstrating associations of novel targets such as time in range (TIR) with pregnancy and neonatal outcomes. A greater understanding of the relationship of various CGM metrics to outcomes in pregnancy complicated by diabetes is needed. It is clear that TIR parameters need to be uniquely lower for pregnant women than for nonpregnant individuals. CGM technology is also an integral part of hybrid closed-loop insulin delivery systems. These insulin delivery systems will be a significant advance in the management of diabetes during pregnancy if they can achieve the pre- and postprandial targets required for pregnancy and optimize TIR.

Seventy-five years of remarkable advances in glucose monitoring have helped to elucidate the relationship of maternal glucose to adverse pregnancy and neonatal outcomes, allowed for more precise insulin dosing to achieve the target goals required to improve these outcomes, and reduced the risk of maternal hypoglycemia. Most recently, continuous glucose monitoring (CGM) is being used with increasing frequency in pregnancy, and novel targets based on CGM data are becoming standardized. Studies have demonstrated that CGM may be a useful adjunct to self-monitoring of blood glucose (SMBG) in pregnancy (1,2). Advances in CGM accuracy have allowed for progress in hybrid closed-loop insulin technology. The application of these new technologies in pregnancies complicated by diabetes will be revolutionary if the algorithms used are able to target the glucose levels necessary for pregnancy.

Outpatient monitoring of glucose in pregnancy began with urine glucose testing in 1945 with the development of Clinitest (Ames, Elkhart, IN), which allowed for a colorimetric method of measuring glucose oxidation (3). Urine glucose measurement was a poor proxy for blood glucose because of the lag in urinary glucose changes relative to blood glucose, individual variations in the threshold for renal glucose excretion, and the absence of urine glucose at the mild to moderate levels of hyperglycemia associated with poor pregnancy outcomes (4). Furthermore, urine glucose could not be used to measure hypoglycemia.

In the absence of an outpatient method of measuring blood glucose, studies of intensified care required lengthy hospitalizations at regular intervals to regulate glucose levels with the increasing insulin doses required for pregnancy. Blood glucose was tested by fasting phlebotomy draw, followed by capillary sticks at 11:00 a.m., 3:00 p.m., and 8:00 p.m. (5; J. Hare, personal communication). These studies demonstrated strong associations between measures of maternal glycemia and pregnancy and neonatal outcomes in women with preexisting diabetes. Perinatal mortality (PM) was linked to average blood glucose in the last weeks of pregnancy such that average blood glucose levels >150 mg/dL had a PM rate of 23.6%; those 100–150 mg/dL had a 15.3% PM rate, and those <100 mg/dL had a 3.8% PM rate (5). Associations of maternal glucose with fetoplacental function, mode of delivery, and neonatal hypoglycemia were noted (5). Reductions in neonatal hyperbilirubinemia and respiratory distress were achieved with second- and third-trimester intensification of treatment toward euglycemia (6).

During the 1980s, home SMBG became accessible and affordable (3). SMBG with a home meter yielded results similar to standard hospitalization protocols (7). Efforts to optimize diabetes control through SMBG were found to be associated with improved outcomes (8). Mean capillary glucose levels <110 mg/dL were associated with reductions in macrosomia, respiratory distress, and neonatal hypoglycemia (9). Correlations were found between mean capillary glucose values and third-trimester A1C (9).

A1C, which provided a longer-term assessment of glycemia, was also an important advance. In 1981, elevations of A1C were found to be associated with a higher risk of congenital malformations (10). A test for A1C, performed early in...
pregnancy, estimates glycemia during organogenesis and provides a valuable assessment of the risk of congenital malformations, which increases exponentially with increasing HbA1C (11). Early-pregnancy HbA1C continues to be the gold-standard glycemic measurement used to determine the risk of birth defects. Because malformations are known to occur before the seventh week of gestation (12) and before most women realize they are pregnant, the importance of optimizing glycemic control before conception for women with preexisting diabetes was recognized. Intensification of treatment for diabetes control early in pregnancy was too late to prevent congenital malformations (13). However, studies of preconception care have demonstrated marked reductions in congenital malformations (14–16), and contraception is crucial to achieving preconception glycemic goals (17).

Of the three most common forms of diabetes in pregnancy (18), gestational diabetes mellitus (GDM) is the most common. Its prevalence depends on ethnicity/country and diagnostic testing method (19). Adverse pregnancy outcomes in women with GDM occur at a significantly higher rate than in women without diabetes (20). However, pregnancies complicated by preexisting type 1 or type 2 diabetes have even greater risks of adverse outcomes, including cesarean delivery, early delivery, maternal hypertensive complications, neonatal infection, macrosomia, respiratory complications, and birth defects, than those with GDM. Total mean costs are highest for patients with type 1 diabetes, followed by those with type 2 diabetes, and then those with GDM (21). Glycemic targets may be readily achievable in patients with GDM but are more challenging in those with type 2 diabetes and most challenging in those with type 1 diabetes, who have a greater potential for both hypoglycemic coma and diabetic ketoacidosis (22). Understandably, the majority of the work done to date on CGM in pregnancy has focused on the population with type 1 diabetes.

**Glycemic Targets in Pregnancy**

The American Diabetes Association’s (ADAs) current recommended glucose targets for the preconception and prenatal periods are shown in Table 1. To achieve these targets, current practice requires SMBG to assess day-to-day glycemic patterns and determine the need for changes in basal or bolus insulin. Assessment of fasting, premeal, and overnight glucose levels helps to determine basal insulin dosing. Postprandial blood glucose patterns determine the appropriateness of mealtime insulin boluses. SMBG testing is required before and after three meals per day for women with preexisting diabetes and fasting and after three meals per day for those with GDM. Patients with type 1 diabetes have greater fluctuations in blood glucose because of their marked insulin deficiency and may require additional testing, including nocturnal assessments, to monitor for hypoglycemia. Usually, 2–3 days of SMBG data are required to determine trends in blood glucose levels before adjusting insulin doses.

The ADA’s 2008 standards of care for preexisting diabetes in pregnancy, described in Table 1, were based on cohort studies aimed at optimizing infant body composition in type 1 diabetes (23–26). The current ADA and American College of Obstetricians and Gynecologists (ACOG) glycemic targets, also described in Table 1, are based on a 1995 study of 66 women with insulin-requiring GDM who were randomized to management based on either premeal or postprandial glucose monitoring, with fasting glucose monitored in both groups (27). Therapeutic ranges were preprandial values of 60–105 mg/dL (3.3–5.9 mmol/L) or postprandial values <140 mg/dL (7.8 mmol/L). This study demonstrated that postprandial, rather than preprandial, blood glucose monitoring improved glycemic control and decreased the risk of neonatal hypoglycemia, macrosomia, and cesarean delivery. A similar randomized controlled trial (RCT) of premeal versus postprandial monitoring using the same therapeutic glucose ranges found reductions in pre-eclampsia and neonatal skinfold thickness in 61 pregnancies complicated by preexisting diabetes (28).

A 2016 Cochrane review (29) examined RCT evidence from three studies of very tight, tight, moderate, and loose categorization of fasting glucose control, which corresponded to approximately <5, <6, <7, and <9 mmol/L (<90, <108, <126, and <162 mg/dL), respectively, in pregnancies complicated by type 1 diabetes. Although the optimal fasting target could not be determined for the <7 mmol/L [<126 mg/dL] categories, there was some evidence of increased preeclampsia, cesarean delivery, and birth weight >90th percentile for “loose” control >7 mmol/L. Postprandial targets could not be evaluated because of heterogeneity. These studies were limited by small size and nonblinding of outcome data and do not sufficiently guide optimal glucose goals.

Normative data in pregnancy pooled from studies of CGM and SMBG have been reported (Table 2) and may help inform glucose targets (30). Future work focused on the use of CGM in pregnancy may further define normal glycemia in pregnancy.

**Accuracy of CGM Systems and Glucose Meters in Pregnancy**

Various CGM systems have been studied in pregnancy. Some are blinded, meaning that the data are recorded but not immediately visible to patients; these systems are downloaded periodically for review by their provider. Some systems are intermittently scanned (iCGM), meaning that the data are available to patients, but patients must scan the device with a smartphone or handheld device to retrieve it.
Other systems are real-time (rtCGM), meaning that they constantly read and display glucose levels and can sound alarms to indicate glycemic highs or lows. Only rtCGM devices have the ability to alert patients to take preemptive action to head off predicted impending hypoglycemia.

The accuracy of glucose meters and CGM devices may be assessed by several different standards (31). The International Organization for Standardization requires that meter-derived glucose values fall within ±15 mg/dL of the comparison method for glucose levels ≤100 and >100 mg/dL for at least 95% of measurements (sometimes referred to as %15/15). CGM accuracy is expected to fall within ±20 mg/dL for the same glucose levels for >90% of measurements (%20/20).

Mean absolute relative difference (MARD) analysis is used to describe the accuracy of CGM systems but also may be applied to blood glucose meters. MARD is calculated by averaging the absolute values of relative differences between the CGM device or meter being evaluated (A) and a reference measurement of high accuracy (B) and reported as a percentage such that the corresponding comparison method results in |(A–B)|/B × 100%. CIs are narrowed (improved) for MARD when an adequate number of paired samples have been tested (32). Glucose meter MARD scores vary, but the top seven meters achieve scores of 5.6–8.2% (33). Current accuracy scores for CGM devices when used in nonpregnant individuals include Dexcom G6 %20/20 92.5%, MARD 9.8% (34); FreeStyle Libre 14-day MARD 9.4% (35); and FreeStyle Libre 2, MARD 9.2% (36) without calibration requirements; and Medtronic Guardian CGM MARD 9.6% with abdominal and 8.7% with arm sensor insertion sites, and a calibration requirement of three to four times daily (37).

In the narrow target ranges that are required during pregnancy, the accuracy of CGM systems at the lower glucose targets is of the utmost importance to identify impending hypoglycemia when it is occurring and avoid unnecessary hypoglycemia alerts when blood glucose levels are in the target range. Studies of CGM devices when used in pregnancy demonstrate similar accuracy as when they are used in nonpregnant subjects: Dexcom G6 %20/20 92.5% and overall MARD 10.3%, although accuracy improves with sensor insertion in the upper arm (%20/20 95.9%, MARD 8.7%) compared with the abdomen or buttock (38); and FreeStyle Libre 14-day %20/20 88.1% and overall MARD 11.8% (39).

### Adoption of CGM in Pregnancy

In a cohort of 700 women, CGM use in pregnancy increased exponentially from 0 (0%) in 2004–2008 to 5 (2.2%) in 2009–2013, to 106 (39.9%) from 2014 to 2017, as accuracy improved and insurance coverage became more broadly available (40). In a 2018 analysis of 4,340 women in the T1D Exchange clinic registry, 214 (4.9%) reported that they were either pregnant or recently pregnant (<1 year) at enrollment (41). Of those women, 69% reported insulin pump use, and 34% reported CGM use, which was a higher usage rate than in women who reported having ever been pregnant (>1 year) or having never been pregnant. The popularity of CGM in pregnancy speaks to the significant improvements in quality of life it can afford users and the perceived improvement in access to data for providers, despite still-limited recommendations on how best to use it in pregnancy and limited outcomes data.

### International Consensus Recommendations on CGM Use and Targets During Pregnancy

In 2017, the International Consensus on Use of Continuous Glucose Monitoring defined and standardized CGM metrics

| TABLE 1 | Recommended Glycemic Targets for Preconception and Pregnancy |
|----------|---------------------------------------------------------------|
|          | Preconception, mg/dL (mmol/L) | Pregnancy, mg/dL (mmol/L) |
|          | ADA 2004 (78)* | ADA 2008 (79)* | ADA 2020 (59)† | ACOG (80)† |
| Fasting  | 80–110 (4.4–6.1) | 60–99 (3.3–5.5) | <95 (<5.3) | <95 (<5.3) |
| 1-hour postprandial | | <140 (<7.8) | <140 (<7.8) |
| Peak postprandial | | 100–129 (5.6–7.2) | |
| 2-hour postprandial | 100–155 (5.6–8.6) | <120 (<6.7) | <120 (<6.7) |

*Preexisting diabetes. †Preexisting diabetes and GDM.

| TABLE 2 | Normal Glucose in Pregnancy |
|----------|-------------------------------|
| Glucose  | mg/dL | mmol/L |
| Fasting  | 71 ± 8 | 3.9 ± 0.4 |
| 1-hour postprandial | 109 ± 13 | 6.0 ± 0.7 |
| 2-hour postprandial | 99 ± 10 | 5.5 ± 0.6 |
| 24-hour mean glucose | 88 ± 10 | 4.9 ± 0.6 |

Data are mean ± SD. Adapted from ref. 31.
These recommendations were revised and simplified in 2019 (43). The consensus panel concluded that time in range (TIR), when used as a metric of glycemic control in addition to A1C, provided “more actionable information than A1C alone.” While A1C provides an estimate of average glucose, the CGM TIR metric puts glucose in the context of patients’ glycemic variability and exposure to hypoglycemia and hyperglycemia.

This work by the consensus panel included standard metric targets for adult patients with diabetes, including in some special populations, one of which was pregnancy in women with type 1 diabetes. These targets are summarized in Table 3. Specific recommendations for pregnancy in women with type 2 diabetes or GDM are limited, as data in these populations are lacking.

The key point is that, in pregnancy complicated by diabetes, TIR has been defined as 63–140 mg/dL (3.5–7.8 mmol/L). This metric requires attention when interpreting CGM data and the ambulatory glucose profile (AGP) reports on which they are summarized, as default settings for nonpregnancy ranges need to be adjusted for pregnancy. Some, but not all, CGM systems can be adjusted. Patients and providers need to understand how to personalize those settings and recognize the limitations of some systems.

The international consensus recommendations for CGM use in pregnancy were limited by reliance primarily on one large, multicenter RCT (44) and a prospective observational study (2) assessing outcomes in pregnancies complicated by type 1 diabetes and a dearth of data in pregnancy complicated by type 2 diabetes or GDM (43).

**Trials of CGM Use During Pregnancy in Women With Type 1 Diabetes**

The majority of research into the use of CGM in pregnancy has focused on women with type 1 diabetes. In these studies, CGM was used as an adjunct to standard care. SMBG fasting and postprandial targets were used as part of standard care. None of the trials were RCTs comparing outcomes using CGM metrics alone versus fasting and postprandial SMBG targets. Taken together, these studies present a compelling case for the added benefits of CGM use in pregnancy complicated by type 1 diabetes. Table 4 summarizes this work.

Early work that included data from only a few intermittent weeks of either blinded (45,46) or rtCGM data (47) yielded mixed results. A 2008 trial by Murphy et al. (46) demonstrated a reduction in birth weight and macrosomia and

### TABLE 3 CGM Metrics and Targets for Adults and Pregnant Adults With Type 1 Diabetes: Recommendations of the International Consensus on Time in Range (43)

| CGM Metric                     | Standard Targets* | Pregnancy Targets |
|-------------------------------|-------------------|-------------------|
| Days CGM should be worn, n    | 14                | 14                |
| Time CGM should be active, %  | >70               | >70               |
| Mean glucose                  | Personalized target† | Personalized target† |
| GMI                            | Personalized target† | Personalized target† |
| Glycemic variability (coefficient of variation), % | <36 | <36 |
| TAR, level 2                  | <5% of time       | <25% of time      |
|                               | >250 mg/dL        | >140 mg/dL        |
|                               | (13.9 mmol/L)     | (7.8 mmol/L)      |
| TAR, level 1                  | <25% of time      | <25% of time      |
|                               | 181–250 mg/dL     | 140 mg/dL         |
|                               | (10.1–13.9 mmol/L)| (7.8 mmol/L)      |
| TIR                           | >70% of time      | >70% of time      |
|                               | 70–180 mg/dL      | 63–140 mg/dL      |
|                               | (3.9–10.0 mmol/L) | (3.5–7.8 mmol/L)  |
| TBR, level 1                  | <4% of time       | <4% of time       |
|                               | 54–69 mg/dL       | 54–62 mg/dL       |
|                               | (3.0–3.8 mmol/L)  | (3.0–3.4 mmol/L)  |
| TBR, level 2 (<54 mg/dL [<3.0 mmol/L]) | <1% of time | <1% of time |

Targets were not recommended for GDM or pregnancy complicated by type 2 diabetes, as more data are needed. Bold type indicates targets that differ for pregnancy. *Goals vary for pediatric, older, and high-risk populations. †ADA recommends an A1C <6% (<42 mmol/mol) in pregnancy or a mean glucose <126 mg/dL (7 mmol/L).
| Study                  | Design                                                | Population                                      | Results                                                      |
|-----------------------|-------------------------------------------------------|-------------------------------------------------|--------------------------------------------------------------|
| Murphy et al., 2008   | Multicenter, open-label RCT of blinded CGM reviewed   | 46 women with type 1 diabetes; 25 women with    | Primary outcome: A1C at 32-36 weeks 5.8 vs. 6.4% (39.9 vs. 46.4 mmol/L) (*P = 0.007)*  |
|                       | every 4 weeks vs. standard care                       | type 2 diabetes                                 | Secondary outcomes: macrosomia: 35 vs. 60% (*P = 0.05)*; no difference in mean gestational age at delivery, preeclampsia, rate of cesarean section, preterm delivery, NICU admission, or neonatal hypoglycemia |
| Secher et al., 2013   | Single-center RCT of rtCGM worn during weeks 8, 12, 21, 27, and 33 plus standard care vs. standard care | 123 women with type 1 diabetes; 31 women with type 2 diabetes | Primary outcome: LGA status 45 vs. 34% (*P = 0.19)  |
|                       |                                                       |                                                 | Secondary outcomes: no difference in A1C at 33 weeks, maternal hypoglycemia, preeclampsia, preterm delivery, or neonatal hypoglycemia |
| Feig et al. (CONCEPTT), 2017 | Multicenter, open-label RCT of rtCGM plus standard care vs. standard care | 215 women with type 1 diabetes | Primary outcome: A1C at 34 weeks mean difference −0.19%, 95% CI −0.34 to −0.03 (*P = 0.0207)*  |
|                       |                                                       |                                                 | Secondary outcomes: TAR 27 vs. 32% (*P = 0.0279)*; TIR 68 vs. 61% (*P = 0.0034)*; neonatal hypoglycemia OR 0.45, 95% CI 0.22-0.89 (*P = 0.0250)*; NICU OR 0.48, 95% CI 0.26-0.86 (*P = 0.0157)*; LGA status OR 0.51, 95% CI 0.28-0.90 (*P = 0.0210)*; birth weight percentile 92 (95% CI 68-99) vs. 96 (95% CI 84-100) (*P = 0.0489); no difference in TBR, maternal weight gain, gestational hypertension, preeclampsia, mode of delivery, maternal length of stay, preterm delivery, or macrosomia |
| Voormolen et al.      | Multicenter, open-label RCT of blinded CGM reviewed   | 109 women with type 1 diabetes; 82 women with    | Primary outcome: macrosomia 31.0 vs. 28.4% (RR 1.06, 95% CI 0.83-1.37)  |
| (GlucoMOMS), 2018     | every 6 weeks vs. standard care                       | type 2 diabetes; 109 women with insulin-requiring GDM | Secondary outcomes: preeclampsia 3.5 vs. 11.6% (RR 0.30, 95% CI 0.12-0.80)*; no difference in pregnancy-induced hypertension, HELLP syndrome, severe hypoglycemia, A1C, birth weight, LGA status, SGA status, preterm birth, neonatal mortality, birth trauma, or neonatal hypoglycemia |

CONTINUED ON P. 124.
However, in a 2013 RCT of intermittent rtCGM in 123 pregnant women with type 1 diabetes and 31 with type 2 diabetes, Secher et al. (47) found no benefits in A1C, severe hypoglycemia, or large-for-gestational-age (LGA) status. Furthermore, in the GlucoMOMS study (45), 300 women with type 1 diabetes (n = 109), type 2 diabetes (n = 82), or GDM (n = 119) were randomized to either standard care or blinded CGM reviewed every 6 weeks plus standard care. This study found no difference in the risk of the primary end point of macrosomia between the two groups. The only secondary end point to demonstrate a significant difference was a reduction in preeclampsia in the CGM group of 3.5 versus 11.6% (relative risk [RR] 0.30, 95% CI 0.12–0.80). Analysis of multiple secondary end points, including A1C and maternal and neonatal hypoglycemia,
showed no further significant differences between groups. Proponents of CGM use in pregnancy might argue that these conflicting results are unsurprising, as the true benefit of CGM use is that it enables actions to adjust for glucose in real time throughout pregnancy—something none of these studies were designed to support.

The largest study of this type to date, the Continuous Glucose Monitoring in Women with Type 1 Diabetes in Pregnancy Trial (CONCEPTT) (1), was a multicenter RCT that compared SMBG plus CGM to SMBG alone in 325 women who were either planning pregnancy (n = 110) or who were pregnant (n = 215). CONCEPTT demonstrated the benefit of CGM in addition to SMBG in pregnant women; it found a small but statistically significant difference in AtC of −0.19% (95% CI −0.34 to −0.03; P = 0.0207) in pregnant women who used CGM versus those who did not. Pregnant women using CGM had statistically significantly less time above range (TAR) than control participants without an increase in time below range (TBR) or in the number of severe hypoglycemic episodes. Perhaps most importantly, there was significant improvement in neonatal outcomes. CONCEPTT found a statistically significant lower incidence of LGA status (odds ratio [OR] 0.51, 95% CI 0.28–0.90, P = 0.0210), a reduction in neonatal hypoglycemia (OR 0.45, 95% CI 0.22–0.89, P = 0.0250), a 1-day reduction in hospital length of stay (P = 0.0091), and fewer neonatal intensive care admissions (OR 0.48, 95% CI 0.26–0.86, P = 0.0157).

**Trials of CGM Use During Pregnancy in Women With Type 2 Diabetes or GDM**

Outcomes data for the use of CGM in type 2 diabetes and GDM are far less robust. To date, no RCTs have specifically studied its use in type 2 diabetes in pregnancy, and the data for its use in GDM are limited (Table 4).

In a 2014 prospective cohort study by Yu et al. (48) of 340 women with GDM who had 4 weeks of blinded CGM plus standard care or standard care alone, those with blinded CGM were found to have a statistically significant lower rate of preeclampsia, improvements in CGM metrics, and a lower rate of a neonatal composite that included premature delivery, macrosomia, LGA status, small-for-gestational-age (SGA) status, obstetric trauma, neonatal hypoglycemia, hyperbilirubinemia, and respiratory distress. However, participants using CGM were more likely to receive insulin than those in the standard care group (27.9 vs. 12.2%, P < 0.001).

A 2016 rtCGM study by Wei et al. (49) found only limited benefits. They reported on 106 women with GDM who were randomized to receive standard care plus CGM for 4 or 8 weeks of their pregnancy (either 24–28 or 28–36 weeks) versus standard care with SMBG. This study found no difference in AtC or obstetric outcomes, including macrosomia, neonatal hypoglycemia, and cesarean delivery, although this finding may have resulted from the short duration of the intervention. Interestingly, more women required insulin therapy in the CGM group than in the control group (31.3 vs. 12.7%, P = 0.020). Excessive maternal weight gain was lower in the CGM group (33 vs. 56.4%, P = 0.039).

In a 2018 RCT of 50 women with insulin-treated GDM randomized to 3 weeks of blinded iCGM plus standard care versus standard care alone, Paramasivam et al. (50) found a lower mean AtC at 37 weeks in the CGM group compared with the control group (33 ± 4 mmol/mol [5.2 ± 0.4%] vs. 38 ± 7 mmol/mol [5.6 ± 0.6%], P < 0.006). Notably, 92% of the CGM group achieved the target AtC goal at 37 weeks compared with 68% of the control group (P = 0.012).

It is unclear why these studies of blinded CGM in GDM demonstrated improved glycemic control, whereas the studies of blinded CGM use in type 1 diabetes did not. One could hypothesize that the difference in outcomes between the trials of blinded intermittent CGM use in type 1 diabetes and those in GDM could be that the level of diabetes education, attention to monitoring, and self-empowerment to adjust insulin in the type 1 diabetes population were higher at baseline, so the retrospective CGM data in GDM improved that population’s understanding of their diabetes more and increased their interventions to control their glucose more than in the women in the type 1 diabetes trials.

**Comparison of rtCGM to iCGM in Pregnancy**

There are limited data comparing differences in outcomes between continuous use of rtCGM and iCGM in pregnancy. In their observational study of 186 women with type 1 diabetes (92 using rtCGM and 94 using iCGM), Kristensen et al. (2) did not find a difference in neonatal outcomes between participants who used rtCGM compared with iCGM. In a small RCT (51), 25 pregnant women with type 1 diabetes using insulin pumps were randomized in the first trimester to either rtCGM or iCGM. Patients using rtCGM achieved lower AtC (6.52 ± 2.13 vs 6.82 ± 0.7%, P < 0.05) and mean glucose (6.92 ± 2.1 vs 7.42 ± 3.4 mmol/L, P < 0.05) in the first trimester compared with those using iCGM. However, while those using rtCGM continued to have lower AtC and mean glucose in their second and third trimesters, the difference was no longer statistically significant. There was no significant difference in the rates of severe hypoglycemic events.
However, rtCGM may be more effective than iCGM at reducing TBR. Kristensen et al. (2) reported a reduction in TBR with rtCGM compared with iCGM. There are also some data in the nonpregnant adult population to support this finding. In an unmasked parallel group study by Reddy et al. (52) of 40 nonpregnant adults with type 1 diabetes who were treated with multiple daily insulin injections and had a history of hypoglycemia, participants were randomized to rtCGM or iCGM for 8 weeks. Those randomized to rtCGM were below the target range 2.4% of the time compared with 6.8% of the time for those with iCGM (median between-group difference −4.3%, P = 0.006).

### Association of CGM Metrics With A1C

In an analysis of four RCTs performed in nonpregnant patients with type 1 diabetes using CGM (n = 545), Beck et al. (53) concluded that TIR and mean glucose are highly correlated with each other but only moderately correlated with A1C and that, for a given TIR, a wide range of A1C values was possible. In this analysis, TIR (70–140 mg/dL [3.9–7.8 mmol/L]) of 70% estimated an A1C of 5.8%; however, the range of A1C this TIR percentage actually represented was 4.4–7.2%. Likewise, TIR (70–180 mg/dL [3.9–10 mmol/L]) of 70% estimated an A1C of 7.0%; however, the range of A1C this TIR actually represented was 5.6–8.3%.

Because A1C is not a direct measure of glycemia and can be affected by a number of factors, there have been calls to replace A1C with CGM metrics such as TIR or mean glucose. This recommendation makes sense, as CGM-derived mean glucose is a more accurate representation of average glucose than A1C, and TIR provides valuable information aimed at minimizing hyperglycemia, hypoglycemia, and glycemic variability that can inform management decisions. However, clinicians and patients have long placed great meaning on A1C values, which have been associated with diabetes outcomes consistently for decades, and there are still relatively few studies demonstrating that relationship with CGM metrics.

This situation has led to various CGM-derived estimations of A1C, such as the glycemic management indicator (GMI), that are based on different calculations of mean glucose in nonpregnant adults. The use of these metrics in pregnancy is problematic, as A1C is known to be significantly lower during pregnancy for a variety of reasons (54). This difference has led to the proposal of a pregnancy-specific estimated average glucose calculation; however, this proposal has not gained widespread acceptance because it is not part of the standard AGP report, of which GMI is a component.

### Association of CGM Metrics With Pregnancy and Neonatal Outcomes

To date, there are no RCTs comparing either different CGM metrics (e.g., mean glucose vs. TIR) or different targets for CGM metrics (e.g., mean glucose 120 vs. 150 mg/dL [6.7 vs. 7.2 mmol/L]) in pregnancies complicated by diabetes. However, there are some data associating CGM metrics with outcomes.

In the 2019 study by Kristensen et al. (2), CGM data were analyzed by trimester in an observational cohort of 186 pregnancies complicated by type 1 diabetes (Table 5). In the first trimester, there was no statistically significant difference in TIR, TAR, TBR, mean glucose, or glucose SD between pregnancies with LGA status and those without. However, A1C was 0.3% (3.7 mmol/mol) higher in the groups with LGA versus without LGA status. In the second and third trimesters, LGA status was associated with higher A1C, mean glucose, and TAR, and lower TIR and TBR. The study found similar associations with a composite of neonatal outcomes that included macrosomia, shoulder dystocia, neonatal hypoglycemia, or admission to the neonatal intensive care unit (NICU) for >24 hours. Outcomes were adjusted for maternal age, smoking status, early-pregnancy BMI, and CGM device. Importantly, the mean maternal glucose observed in the LGA group in the third trimester was 0.5 mmol/L (9 mg/dL) higher than in the no-LGA group with an adjusted OR of 1.57 (95% CI 1.12–2.19, P < 0.001). The mean TIR was 4.6% lower in the LGA group than in the no-LGA group with an adjusted OR of 0.97 (95% CI 0.95–1.00, P = 0.04). The coefficient of variation (glycemic variability measure) was not associated with LGA status.

In a retrospective study of 41 pregnant women with type 1 diabetes using CGM in addition to SMBG, Mulla et al. (55) did not find a relationship between first-, second-, or third-trimester CGM glycemic variability, mean glucose, or A1C with fetal abdominal circumference percentile, estimated fetal weight percentile, or birth weight, except for an association of first-trimester mean glucose with estimated fetal weight percentile. TIR was not an available metric. Accelerated fetal abdominal circumference percentile growth was noted between 26 and 32 weeks.

In a prospective, observational study of 162 women with GDM (56), mean glucose was significantly higher in pregnancies complicated by LGA status (6.2 vs. 5.8 mmol/L [111.6 vs. 104.4 mg/dL], P = 0.025). Neither TIR nor glycemic variability were associated with LGA status. Functional data analysis demonstrated that mean glucose was significantly higher overnight in pregnancies complicated by LGA status versus those without this complication (6.0 ± 1.0 mmol/L [108.0 ± 18 mg/dL] vs. 5.5 ± 0.8 mmol/L [99.0 ± 14.4 mg/dL], P = 0.005).
In a 2015 analysis of CGM data from two previously published studies with a total of 177 pregnant participants (89 with type 1 diabetes and 28 with type 2 diabetes), Law et al. (57) found that mean glucose in each trimester was associated with LGA status, whereas TIR was associated with LGA status only in the second trimester.

In a further analysis of data from CONCEPTT, Scott et al. (58) used functional data analysis to assess differences in glucose temporal patterns between CGM users and SMBG users, insulin pump users and those on a multiple daily injection regimen, and those with pregnancies complicated by LGA status versus those without this complication. This analysis demonstrated that women with pregnancies complicated by LGA status had significantly higher glucose levels for 4.5 hours/day in the first trimester, 16 hours/day in the second trimester, and 14 hours/day in the third trimester than those without the LGA complication. The analysis further demonstrated periods of higher glucose primarily during the day that were not obvious from standard glucose metrics.

| Variable | LGA (n = 98) | No LGA (n = 88) | Adjusted OR (95% CI) | P       |
|----------|--------------|----------------|----------------------|---------|
| **First trimester** | | | | |
| A1C, mmol/mol | 54.1 ± 1.0 | 50.4 ± 9.5 | 1.04 (1.00-1.08) | 0.02* |
| A1C, % | 7.1 ± 1.0 | 6.8 ± 0.9 | — | — |
| Mean glucose, mmol/L | 7.9 ± 1.3 | 7.7 ± 1.5 | 1.16 (0.19-1.49) | 0.24 |
| SD, mmol/L | 3.2 ± 0.8 | 3.2 ± 0.9 | 1.09 (0.73-1.62) | 0.67 |
| Coefficient of variation, % | 40.5 ± 7.2 | 40.6 ± 7.3 | 0.99 (0.95-1.04) | 0.77 |
| TIR, %† | 48.2 ± 13.6 | 51.9 ± 14.5 | 0.98 (0.95-1.00) | 0.07 |
| TAR, % | 44.8 ± 14.6 | 40.9 ± 16.3 | 1.02 (1.00-1.04) | 0.07 |
| TBR, % | 7.0 ± 5.1 | 7.2 ± 5.0 | 0.98 (0.92-1.05) | 0.60 |
| **Second trimester** | | | | |
| A1C, mmol/mol | 46.4 ± 7.4 | 43.7 ± 8.3 | 1.05 (1.01-1.10) | 0.02* |
| A1C, % | 6.4 ± 0.7 | 6.1 ± 0.8 | — | — |
| Mean glucose, mmol/L | 7.6 ± 1.0 | 7.1 ± 1.3 | 1.53 (1.12-2.08) | <0.001* |
| SD, mmol/L | 2.9 ± 0.6 | 2.7 ± 0.7 | 1.65 (1.00-2.74) | <0.05* |
| Coefficient of variation, % | 37.8 ± 5.9 | 37.7 ± 6.7 | 1.00 (0.95-1.06) | 0.93 |
| TIR, %† | 51.8 ± 12.3 | 57.9 ± 14.4 | 0.96 (0.94-0.99) | <0.01* |
| TAR, % | 41.9 ± 12.8 | 34.0 ± 15.9 | 1.04 (1.02-1.07) | <0.001* |
| TBR, % | 6.4 ± 4.5 | 8.0 ± 5.7 | 0.93 (0.87-0.99) | 0.02* |
| **Third trimester** | | | | |
| A1C, mmol/mol | 47.2 ± 6.7 | 44.0 ± 8.2 | 1.06 (1.02-1.11) | <0.01* |
| A1C, % | 6.5 ± 0.6 | 6.2 ± 0.8 | — | — |
| Mean glucose, mmol/L | 7.3 ± 1.1 | 6.8 ± 1.1 | 1.57 (1.12-2.19) | <0.001* |
| SD, mmol/L | 2.6 ± 0.6 | 2.5 ± 0.6 | 1.60 (0.92-2.77) | 0.09 |
| Coefficient of variation, % | 35.9 ± 5.5 | 36.1 ± 6.2 | 0.99 (0.94-1.05) | 0.84 |
| TIR, %† | 57.6 ± 12.8 | 62.2 ± 13.4 | 0.97 (0.95-1.00) | 0.04* |
| TAR, % | 37.0 ± 13.5 | 30.2 ± 15.3 | 1.03 (1.01-1.06) | <0.01* |
| TBR, % | 5.4 ± 4.4 | 7.6 ± 6.4 | 0.92 (0.86-0.98) | <0.01* |

Adjusted for age, smoking status, BMI, and CGM device. Data in LGA and non-LGA columns are mean ± SD. *Statistically significant. †TIR 63–140 mg/dL (3.5–7.8 mmol/L). Adapted from ref. 2.
Future Work

National recommendations on the use of CGM in pregnancy vary, but many support its use in type 1 diabetes (59–61). Further work is needed to demonstrate its value in type 2 diabetes and GDM. In 2019, the International Consensus on Time in Range (43) acknowledged the need for additional work, stating that “to fundamentally change clinical care with use of the new metrics, it would be important to demonstrate the metrics relate to and predict clinical outcomes.” Many questions also remain on how to use CGM technology to the greatest benefit during pregnancy.

Should CGM Targets for GDM and Type 2 Diabetes Vary From Those for Type 1 Diabetes?

This question needs further study. Mean glucose levels in normal pregnancies are considerably lower than targets applied for pregnancies complicated by diabetes. RCTs aimed at studying normal-range glucose targets may be more feasible in pregnancies complicated by GDM and type 2 diabetes than in those in women with type 1 diabetes.

Should TIR or Mean Glucose Replace A1C?

Our understanding of the optimal use of and targets for CGM metrics in type 1 diabetes and pregnancy is still evolving. In CONCEPTT, did the addition of CGM improve neonatal outcomes because of improved adherence to fasting and postprandial targets and therefore A1C or because it introduced the measures of TIR, glycemic variability, or both? Which CGM metrics are most important in predicting specific outcomes?

TIR and mean glucose are highly correlated with each other. Every 5% increase in TIR is associated with an improvement in neonatal outcomes (62), but mean glucose may be more predictive of LGA status. However, TBR should be avoided for maternal well-being. It is possible that, over time, mean glucose will replace A1C as the long-term hyperglycemia exposure metric associated with pregnancy and neonatal outcomes, and a goal of higher TIR and lower TBR may be used as an additional metric to reduce maternal hypoglycemia and possibly improve quality of life and reduce diabetes distress.

What Is the Relationship Between Temporal Variation in Glycemia Seen in Functional Data Analysis and the Underlying Pathophysiology of Adverse Pregnancy and Neonatal Outcomes?

As previously mentioned, a 2015 functional data analysis of CGM data from 117 women with diabetes (89 with type 1 diabetes and 29 with type 2 diabetes) who had participated in either of two RCTs of CGM use in pregnancy demonstrated higher daytime glucose patterns in pregnancies that resulted in an LGA infant (57). However, nocturnal hyperglycemia was associated with LGA status in GDM (56). More work is needed to understand the relationship between temporal variations in glycemia and the underlying pathophysiology of adverse outcomes.

What Is the Relationship Between CGM Metrics and Temporal Glycemic Variations and the Normal Physiology of Pregnancy?

The GOMOMS (Glycemic Observation and Metabolic Outcomes in Mothers and Offspring) study, a prospective, observational study designed to characterize maternal glucose over the course of pregnancy using CGM and oral glucose tolerance testing data, may help to answer this question (63).

What Is the Cost-Benefit Ratio of CGM Use in Pregnancy?

A financial model by the CONCEPTT collaborative predicted significant cost savings with CGM use in pregnant women with type 1 diabetes. The model was based on the U.K. National Health Service structure and estimated an annual cost of care for such pregnancies nationally of bolus insulin doses. Neither TIR nor mean glucose provide the necessary level of granularity for this purpose.
£23,725,648 (USD $30,843,342) compared with £14,165,187 (USD $18,414,743) with universal CGM use during pregnancy in women with type 1 diabetes (64). Obviously, more work is needed in this area, both based on a U.S. care model and in patients with either type 2 diabetes or GDM.

What Is the Role of Hybrid Closed-Loop Insulin Delivery Systems in Pregnancy?

More data on the use of insulin pumps in pregnancy are critically needed. Although many practitioners and patients prefer to use insulin pumps in pregnancy complicated by type 1 diabetes, early work looking at the use of pumps has had mixed results (44,65–68). Given the progressive increase in insulin requirement during pregnancy (69), this state seems like the ideal one in which to demonstrate a benefit in glycemic control with a CGM-enabled hybrid closed-loop (HCL) insulin delivery system. To date, the data on HCL insulin delivery for pregnant women are limited to two small studies in women with type 1 diabetes (70,71).

Conclusion

To date, optimal glycemic control in pregnancy has aimed to reduce adverse pregnancy and neonatal outcomes by lowering average glucose, as represented by A1C, while minimizing maternal hypo- and hyperglycemia. CGM provides a powerful new tool that promises to help achieve the goals of improved outcomes in multiple ways.

The first is by potentially providing a more accurate representation of mean blood glucose. A1C has been used for decades as a proxy for mean blood glucose, and pregnancy outcomes are strongly associated with A1C. The ADA recommends an A1C <6% (42 mmol/mol) in pregnancy. This recommendation is based on multiple studies in pregnant women with type 1 diabetes, type 2 diabetes, or GDM, demonstrating the strong relationship of A1C to maternal and neonatal outcomes (12,72–77). There are strong arguments that CGM-derived mean (interstitial) glucose may provide a more accurate representation of mean blood glucose than A1C, both in and out of pregnancy. If A1C were to be replaced by a more accurate CGM metric, one would assume that the CGM metrics most representative of mean blood glucose (i.e., mean glucose) would be the most closely associated with diabetes complications. However, accuracy currently limits CGM use in pregnancy because CGM systems are less accurate than the best meters and therefore should be used only as an adjunct to meter glucose testing. CGM accuracy may continue to improve with ongoing innovation. To date, no group has provided specific recommended CGM targets for mean glucose in pregnancy.

The second way in which CGM may improve glycemic management during pregnancy is by the introduction of TIR as a new metric to be used in addition to some estimation of mean blood glucose. TIR is especially valuable in patients with type 1 diabetes and those with risk factors for severe hypoglycemia. By definition, more time spent in the target range indicates less time spent in the undesirable below- and above-target ranges. CONCEPT demonstrated that an increasing percentage of TIR is associated with improved outcomes. However, the proposed TIR target of 63–140 mg/dL (3.5–7.8 mmol/L) does not distinguish between optimal overnight/fasting/preprandial glucose targets and postprandial glucose targets that are necessary for data-driven basal and bolus insulin adjustments, respectively, that are required throughout pregnancy. For example, although meeting the TIR target, CGM glucose levels of 140 mg/dL (7.8 mmol/L) overnight and 1-hour postprandial glucose levels of 63 mg/dL (3.5 mmol/L) are both unacceptable. Thus, TIR cannot be used as a stand-alone metric.

The third contribution of CGM to diabetes management during pregnancy, and the one that perhaps accounts for its popularity with patients and providers, is the improvement in patient experience (e.g., resulting from a reduced need for SMBG and reductions in hypoglycemia and hyperglycemia) and provider experience (e.g., resulting from increased ease of access to better and more standardized data).

A fourth benefit, and perhaps the most important for neonatal outcomes, is that CGM provides far more data and therefore more opportunities to improve glucose than SMBG alone. Patients are empowered to manage their glucose levels, since more data are easily presented to them. As HCL insulin delivery systems continue to evolve, CGM will become even more important as an integral part of that technology. Some CGM-enabled HCL systems now have algorithms that achieve the overnight and preprandial glucose targets that guidelines recommend. A further innovation in CGM technology would be to identify optimal TIR for postprandial periods separately from overnight and preprandial periods, allowing for the achievement of even tighter glycemic control. Again, much work is needed.

Acknowledgments

J.A. W. and F.M. B. both researched data, contributed to discussion, and wrote and edited the manuscript. Both are guarantors of this work and, as such, had full access to all the data in the review and take responsibility for the integrity of the data and the accuracy of the data analysis.

Duality of Interest

No potential conflicts of interest relevant to this article were reported.
REFERENCES

1. Feig DS, Donovan LE, Corcoy R, et al.; CONCEPTT Collaborative Group. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet 2017;390:2347–2359

2. Kristensen K, Øgge LE, Sengpiel V, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes: an observational cohort study of 186 pregnancies. Diabetologia 2019;62:1143–1153

3. Hirsch IB. History of glucose monitoring. In Role of Continuous Glucose Monitoring in Diabetes Treatment. Hirsch IB, Battelino T, Peters AL, Chamberlain JJ, Alessio G, Bergenstal RM, Eds. Arlington, Va., American Diabetes Association, 2018

4. Skysler JS, Lasky IA, Sklyer DL, Robertson EG, Mintz DH. Home blood glucose monitoring as an aid in diabetes management. Diabetes Care 1978;1:150–157

5. Karlsson K, Kjellmer I. The outcome of diabetic pregnancies in relation to the mother’s blood sugar level. Am J Obstet Gynecol 1972;112:213–220

6. Coustan DR, Berkowitz RL, Hobbins JC. Tight metabolic control of overt diabetes in pregnancy. Am J Med 1980;68:845–852

7. Hanson U, Person B, Enochsson E, et al. Self-monitoring of blood glucose by diabetic women during the third trimester of pregnancy. Am J Obstet Gynecol 1984;150:817–821

8. Jovanovic L, Druzin M, Peterson CM. Effect of euglycemia on the outcome of pregnancy in insulin-dependent diabetic women as compared with normal control subjects. Am J Med 1981;71:921–927

9. Landon MB, Gabbe SG, Piana R, Mennuti MT, Main EK. Neonatal morbidity in pregnancy complicated by diabetes mellitus: predictive value of maternal glycemic profiles. Am J Obstet Gynecol 1987;156:1089–1095

10. Miller E, Hare JW, Cloherty JP, et al. Elevated maternal hemoglobin A1c in early pregnancy and major congenital anomalies in infants of diabetic mothers. N Engl J Med 1981;304:1331–1334

11. Guerin A, Nisenbaum R, Ray JG. Use of maternal GHb concentration to estimate the risk of congenital anomalies in the offspring of women with pregestational diabetes. Diabetes Care 2007;30:1920–1925

12. Mills JL, Baker L, Goldman AS. Malformations in infants of diabetic mothers occur before the seventh gestational week: implications for treatment. Diabetes 1979;28:292–293

13. Mills JL, Knopp RH, Simpson JL, et al. Lack of relation of increased malformation rates in infants of diabetic mothers to glycemic control during organogenesis. N Engl J Med 1988;318:671–676

14. Fuhrmann K, Reiher H, Semmler K, Fischer F, Fischer M, Glöckner E. Prevention of congenital malformations in infants of insulin-dependent diabetic mothers. Diabetes Care 1983;6:219–223

15. Steel JM, Johnstone FD, Hepburn DA, Smith AF. Can pregestational care of diabetic women reduce the risk of abnormal babies? BMJ 1990;301:1070–1074

16. Kitzmiller JL, Gavin LA, Gin GD, Jovanovic-Peterson L, Main EK, Zigang WD. Preconception care of diabetes: glycemic control prevents congenital anomalies. JAMA 1991;265:731–736

17. Steel JM, Duncan LJ. Contraception for the insulin-dependent diabetic woman: the view from one clinic. Diabetes Care 1980;3:557–560

18. American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2020. Diabetes Care 2020;43(Suppl. 1):S14–S31

19. Brown FM, Wyckoff J. Application of one-step IADPSG versus two-step diagnostic criteria for gestational diabetes in the real world: impact on health services, clinical care, and outcomes. Curr Diab Rep 2017;17:85

20. Metzger BE, Gabbe SG, Persson B, et al.; International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010;33:676–682

21. Jovanović L, Liang Y, Weng W, Hamilton M, Chen L, Wintfeld N. Trends in the incidence of diabetes, its clinical sequelae, and associated costs in pregnancy. Diabetes Metab Res Rev 2015;31:707–716

22. Balsells M, Garcia-Patterson A, Gich I, Corcoy R. Maternal and fetal outcome in women with type 2 versus type 1 diabetes mellitus: a systematic review and metaanalysis. J Clin Endocrinol Metab 2009;94:4284–4291

23. Jovanovic-Peterson L, Peterson CM, Reed GF, et al. Maternal postpartum glucose levels and infant birth weight: the Diabetes in Early Pregnancy Study. Am J Obstet Gynecol 1991;164:103–111

24. Combs CA, Gunderson E, Kitzmiller JL, Gavin LA, Main EK. Relationship of fetal macrosomia to maternal postpartum glucose control during pregnancy. Diabetes Care 1992;15:1251–1257

25. Kitzmiller JL, Block JM, Brown FM, et al. Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care. Diabetes Care 2008;31:1060–1079

26. Persson B, Hanson U. Insulin dependent diabetes in pregnancy: impact of maternal blood glucose control on the offspring. J Paediatr Child Health 1993;29:20–23

27. de Veciana M, Major CA, Morgan MA, et al. Postpartal versus prepartal blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med 1995;333:1237–1241

28. Manderson JG, Patterson CC, Hadden DR, Traub AI, Ennis C, McCance DR. Prepartal versus postpartal blood glucose monitoring in type 1 diabetic pregnancy: a randomized controlled clinical trial. Am J Obstet Gynecol 2003;189:507–512

29. Middleton P, Crowther CA, Simmonds L. Different intensities of glycaemic control for pregnant women with pre-existing diabetes. Cochrane Database Syst Rev 2016;CD008540

30. Hernandez TL, Friedman JE, Van Pelt RE, Barbour LA. Patterns of glycaemia in normal pregnancy: should the current therapeutic targets be challenged? Diabetes Care 2011;34:1660–1668

31. Freckmann G, Pleus S, Grady M, Setford S, Levy B. Measures of accuracy for continuous glucose monitoring and blood glucose monitoring devices. J Diabetes Sci Technol 2019;13:575–583

32. Reiterer F, Polterauer P, Schoemaker M, et al. Significance and reliability of MARD for the accuracy of CGM systems. J Diabetes Sci Technol 2017;11:59–67

33. Eklhospour L, Mondesir D, Lautsch N, et al. Comparative accuracy of 17 point-of-care glucose meters. J Diabetes Sci Technol 2017;11:558–566

34. Shah VN, Laffel LM, Wadwa RP, Garg SK. Performance of a factory-calibrated real-time continuous glucose monitoring system utilizing an automated sensor applicator. Diabetes Technol Ther 2018;20:428–433

35. Han D. FDA approves FreeStyle Libre 14 Day flash glucose monitoring system. Available from https://www.empr.com/home/news/fda-approves-freestyle-libre-14-day-flash-glucose-monitoring-system. Accessed 15 November 2020

36. Abbott Diabetes. FreeStyle Libre 2 accuracy. Available from https://provider.myfreestyle.com/accuracy.html. Accessed 15 November 2020

37. Medtronic. Guardian Sensor 3 continuous glucose monitoring system. Available from https://www.medtronic.com/us-en/healthcare-professionals/products/diabetes/continuous-glucose-monitoring-systems/guardian-sensor-3.html. Accessed 15 November 2020
38. Castorino K, Polsky S, O’Malley G, et al. Performance of the Dexcom G6 continuous glucose monitoring system in pregnant women with diabetes. Diabetes Technol Ther 2020;22:943–947

39. Scott EM, Bilous RW, Kautzky-Willer A. Accuracy, user acceptability, and safety evaluation for the FreeStyle Libre flash glucose monitoring system when used by pregnant women with diabetes. Diabetes Technol Ther 2018;20:180–188

40. Helman S, James-Todd TM, Wang Z, et al. Time trends in pregnancy-related outcomes among women with type 1 diabetes mellitus, 2004–2017. J Perinatol 2020;40:1145–1153

41. Polsky S, Wu M, Bode BW, et al. Diabetes technology use among pregnant and nonpregnant women with T1D in the T1D Exchange. Diabetes Technol Ther 2018;20:517–523

42. Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitoring. Diabetes Care 2017;40:1631–1640

43. Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range. Diabetes Care 2019;42:1593–1603

44. Feig DS, Corcoy R, Donovan LE, et al.; CONCEPTT Collaborative Group. Pumps or multiple daily injections in pregnancy involving type 1 diabetes: a prespecified analysis of the CONCEPTT randomized trial. Diabetes Care 2018;41:2471–2479

45. Voormolen DN, DeVries JH, Sanson RME, et al. Continuous glucose monitoring during diabetic pregnancy (GlucoMOMS): a multicentre randomized controlled trial. Diabetes Obes Metab 2018;20:1894–1902

46. Murphy HR, Rayman G, Lewis K, et al. Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial. BMJ 2008;337:a1680

47. Secher AL, Ringholm L, Andersen HU, Damm P, Mathiesen ER. The effect of real-time continuous glucose monitoring in pregnant women with diabetes: a randomized controlled trial. Diabetes Care 2013;36:1877–1883

48. Yu F, Lu L, Liang Z, et al. Continuous glucose monitoring effects on maternal glycemic control and pregnancy outcomes in patients with gestational diabetes mellitus: a prospective cohort study. J Clin Endocrinol Metab 2014;99:4674–4682

49. Wei Q, Sun Z, Yang Y, Yu H, Ding H, Wang S. Effect of a CGMS and SMBG on maternal and neonatal outcomes in gestational diabetes mellitus: a randomized controlled trial. Sci Rep 2016;6:19920

50. Paramasivam SS, Chhina K, Singh AKK, et al. Continuous glucose monitoring results in lower HbA1c in Malaysian women with insulin-treated gestational diabetes: a randomized controlled trial. Diabet Med 2018;35:1118–1129

51. Petrovski G, Dimitrovski C, Bogoev M, Milenkovic T, Ahmeti I, Bitovska I. Is there a difference in pregnancy and glycemic outcome in patients with type 1 diabetes on insulin pump with constant or intermittent glucose monitoring? A pilot study. Diabetes Technol Ther 2011;13:1109–1113

52. Reddy M, Jugnee N, El Laboudi A, Spanudakis E, Anantharaja S, Oliver N. A randomized controlled pilot study of continuous glucose monitoring and flash glucose monitoring in people with type 1 diabetes and impaired awareness of hypoglycemia. Diabet Med 2018;35:483–490

53. Beck RW, Bergenstal RM, Cheng P, et al. The relationships between time in range, hyperglycemia metrics, and HbA1c. J Diabetes Sci Technol 2019;13:614–626

54. Law GR, Gilthorpe MS, Secher AL, et al. Translating HbA1c measurements into estimated average glucose values in pregnant women with diabetes. Diabetologia 2017;60:618–624

55. Mulla BM, Noor N, James-Todd T, et al. Continuous glucose monitoring, glycemic variability, and excessive fetal growth in pregnancies complicated by type 1 diabetes. Diabetes Technol Ther 2018;20:413–419

56. Law GR, Alnaji A, Alrefaii L, et al. Suboptimal nocturnal glucose control is associated with large for gestational age in treated gestational diabetes mellitus. Diabetes Care 2019;42:810–815

57. Law GR, Ellison GT, Secher AL, et al. Analysis of continuous glucose monitoring in pregnant women with diabetes: distinct temporal patterns of glucose associated with large-for-gestational-age infants. Diabetes Care 2015;38:1319–1325

58. Scott EM, Feig DS, Murphy HR; CONCEPTT Collaborative Group. Continuous glucose monitoring in pregnancy: importance of analyzing temporal profiles to understand clinical outcomes. Diabetes Care 2020;43:1178–1184

59. American Diabetes Association. 14. Management of diabetes in pregnancy: Standards of Medical Care in Diabetes—2020. Diabetes Care 2020;43(Suppl. 1):S183–S192

60. Peters AL, Ahmann AJ, Battelino T, et al. Diabetes technology—continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2016;101:3922–3937

61. Feig DS, Berger H, Donovan L, et al.; Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes and pregnancy. Can J Diabetes 2018;42(Suppl. 1):S255–S262

62. Murphy HR. Continuous glucose monitoring targets in type 1 diabetes pregnancy: every 5% time in range matters. Diabetologia 2019;62:1123–1128

63. Northwestern University. GOMOMS Clinical Center RFA. Available from https://www.feinberg.northwestern.edu/sites/nudcc/docs/gomoms-rfa.docx. Accessed 17 February 2021

64. Murphy HR, Feig DS, Sanchez JJ, de Portu S; CONCEPTT Collaborative Group. Modelling potential cost savings from use of real-time continuous glucose monitoring in pregnant women with type 1 diabetes. Diabet Med 2019;36:1652–1658

65. Kekäläinen P, Juuti M, Wallé T, Laatikainen T. Continuous subcutaneous insulin infusion during pregnancy in women with complicated type 1 diabetes is associated with better glycemic control but not with improvement in pregnancy outcomes. Diabetes Technol Ther 2016;18:144–150

66. Kallas-Koeman MM, Kong JM, Kline JA, et al. Insulin pump use in pregnancy is associated with lower HbA1c without increasing the rate of severe hypoglycaemia or diabetic ketoacidosis in women with type 1 diabetes. Diabetologia 2014;57:681–689

67. Kjällhede K, Benfortor K, Kristensen K, et al. Glycemic, maternal and neonatal outcomes in women with type 1 diabetes using continuous glucose monitoring during pregnancy: pump vs multiple daily injections, a secondary analysis of an observational cohort study. Acta Obstet Gynecol Scand. Epub ahead of print on 11 November 2020 (doi: 10.1111/aogs.14039)

68. Abell SK, Suen M, Pease A, et al. Pregnancy outcomes and insulin requirements in women with type 1 diabetes treated with continuous subcutaneous insulin infusion and multiple daily injections: cohort study. Diabetes Technol Ther 2017;19:280–287

69. Roeder HA, Moore TR, Ramos GA. Insulin pump dosing across gestation in women with well-controlled type 1 diabetes mellitus. Am J Obstet Gynecol 2012;207:324.e1–324.e5

70. Stewart ZA, Wilinska ME, Hartnell S, et al. Day-and-night closed-loop insulin delivery in a broad population of pregnant women with type 1 diabetes: a randomized controlled crossover trial. Diabetes Care 2018;41:1391–1399

71. Stewart ZA, Wilinska ME, Hartnell S, et al. Closed-loop insulin delivery during pregnancy in women with type 1 diabetes. N Engl J Med 2016;375:644–654

72. Nielsen GL, Møller M, Sørensen HT. HbA1c in early diabetic pregnancy and pregnancy outcomes: a Danish population-based
cohort study of 573 pregnancies in women with type 1 diabetes. Diabetes Care 2006;29:2612–2616
73. Suhonen L, Hiilesmaa V, Teramo K. Glycaemic control during early pregnancy and fetal malformations in women with type I diabetes mellitus. Diabetologia 2000;43:79–82
74. McElvy SS, Miodovnik M, Rosenn B, et al. A focused preconceptional and early pregnancy program in women with type 1 diabetes reduces perinatal mortality and malformation rates to general population levels. J Matern Fetal Med 2000;9:14–20
75. Ho YR, Wang P, Lu MC, Tseng ST, Yang CP, Yan YH. Associations of mid-pregnancy HbA1c with gestational diabetes and risk of adverse pregnancy outcomes in high-risk Taiwanese women. PLoS One 2017;12:e0177563
76. Cyganek K, Skupien J, Katra B, et al. Risk of macrosomia remains glucose-dependent in a cohort of women with pregestational type 1 diabetes and good glycemic control. Endocrine 2017;55:447–455
77. Temple RC, Aldridge V, Stanley K, Murphy HR. Glycaemic control throughout pregnancy and risk of pre-eclampsia in women with type 1 diabetes. BJOG 2006;113:1329–1332
78. American Diabetes Association. Preconception care of women with diabetes. Diabetes Care 2004;27(Suppl. 1):S76–S78
79. American Diabetes Association. Standards of medical care in diabetes—2008. Diabetes Care 2008;31(Suppl. 1):S12–S54
80. ACOG practice bulletin no. 190: gestational diabetes mellitus. Obstet Gynecol 2018;131:e49–e64